Flu-Like Symptoms as a Complication of Botulinum Toxin Therapy
Botulinum toxin (BoNT) has become a revolutionary treatment for many neurological, autonomic, gastrointestinal, genitourinary, and cosmetic disorders. The use of this treatment requires expertise in dosage calculations and application technique to avoid potential side effects. Most adverse events (AEs) related to BoNT are local and related to its mechanism of action, i.e., paralysis of unwanted muscles. However, systemic AEs may also be observed. Flu-like symptoms (FLS) are well recognized AEs in patients treated with BoNT; however there is a paucity of information regarding the frequency, clinical impact, and associated risk factors of this particular complication.
Between December 1989 and May 2003, 1,437 reports of BoNT-related AEs were registered at the Food and Drug Administration (FDA). FLS were reported in 4.6% of serious, and 3.2% of non-serious side effects.
In this study, the investigators aim to assess prospectively the frequency, clinical characteristics, and risk factors for development of FLS in a group of patients affected with diverse movement disorders and treated with BoNT type A at the Parkinson's Disease Center and Movement Disorders Clinic (PDCMDC) of Baylor College of Medicine (BCM). The investigators will also assess biomarker of inflammatory response in those patients who develop FLS after treatment with BoNT.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Flu-Like Symptoms as a Complication of Botulinum Toxin Therapy|
- The frequency of FLS will be estimated by number of patients and number of Botox treatments [ Time Frame: Eight months or 2 treatment cycles ] [ Designated as safety issue: Yes ]The frequency of FLS will be estimated by number of patients and number of Botox treatments
|Study Start Date:||April 2011|
|Study Completion Date:||July 2012|
|Primary Completion Date:||June 2012 (Final data collection date for primary outcome measure)|
Flu-like symtoms, incidence
The frequency of FLS will be estimated by number of patients and number of Botox treatments.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01337453
|United States, Texas|
|Baylor College of Medicine, Dept. of Neurology|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Joseph Jankovic, MD||Baylor College of Medicine|